Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Jul 28, 2026
Galmed Pharmaceuticals announced the development of an orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, targeting a $6 billion market. The company reports that this new formulation demonstrates approximately 150% higher systemic bioavailability and a 300% significant increase in CNS exposure compared to conventional oral administration. The ODF formulation is designed to dissolve within seconds without water, addressing dysphagia which affects up to 80% of Parkinson's patients during disease progression.
Key figures
- Market Size Usd
- $6 billion
- Cns Exposure Increase
- 300%
- Dysphagia Prevalence
- 80%
- Bioavailability Increase
- 150%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.